Opportunity Information: Apply for RFA DK 14 501
Apply for RFA DK 14 501
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Mar 12, 2014 and posted on Mar 12, 2014.
- Applicants must submit their applications by May 28, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $10,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $400,000.00 in funding.
- The number of recipients for this funding is limited to 23 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) (U01) funding opportunity (RFA-DK-14-501) is a National Institutes of Health (NIH) cooperative agreement designed to keep the long-running DPPOS cohort under active follow-up. This announcement is described as a limited competition, meaning it is intended for a defined set of eligible applicants (as specified in the full FOA) rather than being broadly open to all potential research institutions. The project sits in the NIH mission area covering diabetes and related chronic diseases, and it focuses on maintaining and extending the scientific value of one of the most influential diabetes prevention cohorts ever assembled.
At the center of this opportunity is the Diabetes Prevention Program (DPP), a multi-center randomized controlled clinical trial that originally tested whether type 2 diabetes could be prevented or delayed in people at high risk. The DPP produced landmark findings: an intensive lifestyle intervention reduced the incidence of type 2 diabetes by about 58 percent, and metformin reduced incidence by about 31 percent, each compared with placebo. Those results helped shape clinical guidelines and public health programs for diabetes prevention. After the original trial ended, participants continued in the Diabetes Prevention Program Outcomes Study (DPPOS) so researchers could understand what happens years later, including whether the early interventions have lasting effects on health outcomes beyond the initial diabetes diagnosis.
This FOA specifically supports the continuation of DPPOS follow-up to answer longer-term questions that cannot be resolved during a typical clinical trial timeframe. Earlier DPPOS efforts were aimed at understanding long-term diabetes development and microvascular complications, which include problems like diabetic eye disease, kidney disease, and neuropathy that arise from chronic hyperglycemia. The current emphasis highlighted in the announcement is to extend follow-up in order to examine whether early exposure to metformin affects the development of major later-life outcomes, particularly cardiovascular disease and cancer. In practical terms, this means continued participant contact, data collection, event ascertainment, and coordination across multiple clinical centers so that outcomes can be tracked consistently and analyzed with adequate statistical power.
Because this is a cooperative agreement (U01), NIH is expected to have substantial scientific and programmatic involvement during the project period, beyond the normal stewardship of a traditional research grant. Cooperative agreements typically involve close coordination between the awardees and NIH staff on study governance, protocol implementation, quality control, and milestone-driven progress. The continuation of a cohort study like DPPOS also tends to rely on well-established infrastructure: standardized procedures for clinical assessments, rigorous adjudication of cardiovascular events, careful documentation of cancer outcomes, and harmonized data management systems that preserve continuity with prior DPP and DPPOS datasets.
Funding details in the notice indicate an estimated total funding level of about $10,000,000, with an expected 23 awards and an award ceiling of $400,000. There is no cost sharing or matching requirement. The activity category is listed under health, with a focus relevant to food and nutrition as well as diabetes prevention and chronic disease outcomes. The CFDA listing is 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research), aligning the opportunity with NIH institutes and programs that support diabetes-related research.
Eligibility is limited and further clarified in the FOA text, but the summary provided states that non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply. At the same time, foreign components, as defined in the NIH Grants Policy Statement, are allowed, which generally means certain project elements may involve foreign participation under NIH rules while the applicant organization itself must be eligible and domestic. The opportunity was posted on March 12, 2014, with an original and current closing date of May 28, 2014, and an archive date of June 28, 2014, indicating it is no longer open but remains available as a record of the program solicitation.
Overall, the grant opportunity is about preserving and extending the long-term scientific return on the DPP and DPPOS investments by continuing rigorous follow-up of a unique, well-characterized cohort. The primary scientific goal emphasized here is to determine whether early metformin treatment influences major downstream health outcomes, especially cardiovascular disease and cancer, while maintaining the longitudinal framework needed to evaluate how early prevention strategies translate into real-world long-term benefits and risks.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity is the Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) (U01), Funding Opportunity Announcement (FOA) number RFA-DK-14-501. It is an NIH cooperative agreement intended to support continued follow-up of the long-running DPPOS participant cohort.
Which agency is offering this grant?
The funding opportunity is offered by the National Institutes of Health (NIH), within the mission area that covers diabetes and related chronic diseases.
What does "limited competition" mean in this FOA?
"Limited competition" means the opportunity is intended for a defined set of eligible applicants, as specified in the full FOA, rather than being broadly open to all institutions.
What type of award mechanism is used?
The mechanism is a U01 cooperative agreement. This award type typically involves substantial scientific and programmatic involvement by NIH staff during the project period.
How is a U01 cooperative agreement different from a standard research grant?
Based on the description provided, NIH is expected to be more involved than in a traditional grant through coordination on study governance, protocol implementation, quality control, and milestone-driven progress.
What is the Diabetes Prevention Program (DPP)?
The DPP was a multi-center randomized controlled clinical trial that tested whether type 2 diabetes could be prevented or delayed in people at high risk.
What were the landmark findings from the original DPP trial?
The DPP found that an intensive lifestyle intervention reduced the incidence of type 2 diabetes by about 58 percent compared with placebo, and metformin reduced incidence by about 31 percent compared with placebo.
What is the Diabetes Prevention Program Outcomes Study (DPPOS)?
DPPOS is the long-term follow-up study of participants from the original DPP trial, designed to understand longer-term health outcomes years after the initial interventions.
What is the main purpose of this continuation FOA?
The purpose is to keep the DPPOS cohort under active follow-up to answer long-term research questions that cannot typically be resolved during a standard clinical trial timeframe.
What scientific questions are emphasized in this continuation?
The emphasis described is extending follow-up to examine whether early exposure to metformin affects major later-life outcomes, particularly cardiovascular disease and cancer.
What kinds of outcomes were studied in earlier DPPOS work?
Earlier efforts focused on long-term diabetes development and microvascular complications, including diabetic eye disease, kidney disease, and neuropathy.
What activities are supported to continue the DPPOS follow-up?
The described activities include continued participant contact, data collection, event ascertainment, and coordination across multiple clinical centers so outcomes can be tracked consistently and analyzed with adequate statistical power.
Why is multi-center coordination important for this project?
The continuation study relies on consistent tracking and standardized processes across multiple clinical centers to maintain continuity with prior DPP and DPPOS datasets and to support reliable long-term outcome analyses.
What infrastructure is implied as important for a cohort continuation like DPPOS?
The description highlights the need for standardized clinical assessment procedures, rigorous adjudication of cardiovascular events, careful documentation of cancer outcomes, and harmonized data management systems that preserve continuity with existing datasets.
What is the estimated total funding level for this opportunity?
The estimated total funding level is about $10,000,000.
How many awards were expected?
The notice indicates an expectation of 23 awards.
What is the award ceiling?
The award ceiling is listed as $400,000.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
What is the activity category or topic area?
The activity category is listed under health, with a focus relevant to food and nutrition as well as diabetes prevention and chronic disease outcomes.
What is the CFDA number associated with this opportunity?
The CFDA listing is 93.847, titled Diabetes, Digestive, and Kidney Diseases Extramural Research.
Who is eligible to apply?
Eligibility is limited and is further clarified in the full FOA. The summary provided states that non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply.
Are foreign components allowed?
Yes. The summary notes that foreign components, as defined in the NIH Grants Policy Statement, are allowed, even though foreign institutions and non-U.S. components of U.S. organizations are not eligible as applicants.
When was the opportunity posted?
The opportunity was posted on March 12, 2014.
What were the closing dates?
The original and current closing date listed is May 28, 2014.
When was the opportunity archived?
The archive date is June 28, 2014.
Is this funding opportunity still open?
No. Based on the provided dates (closing date in 2014 and an archive date in 2014), it is no longer open and remains available as a record of the solicitation.
What is the overall rationale for continuing DPPOS?
The stated rationale is to preserve and extend the long-term scientific return from the original DPP and subsequent DPPOS investments by maintaining rigorous follow-up of a unique, well-characterized cohort.
What is the primary scientific goal highlighted in the description?
The primary goal emphasized is determining whether early metformin treatment influences major downstream health outcomes, especially cardiovascular disease and cancer, within a longitudinal framework that can assess long-term benefits and risks.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: Street Outreach Program
Previous opportunity: Basic Center Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 14 501
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 14 501) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition Continuation of the Type 2 Diabetes in Adolescents and Youth (TODAY) Study (U01) Apply for RFA DK 14 502 Funding Number: RFA DK 14 502 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $10,000,000 |
| Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01) Apply for RFA DK 14 003 Funding Number: RFA DK 14 003 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $300,000 |
| Limited Competition for the Data Coordinating Center of Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01) Apply for RFA DK 14 503 Funding Number: RFA DK 14 503 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $2,500,000 |
| Reagents for Glucagon and Incretin Research (R41/R42) Apply for PA 14 204 Funding Number: PA 14 204 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Reagents for Glucagon and Incretin Research (R43/R44) Apply for RFA DK 14 008 Funding Number: RFA DK 14 008 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Diabetes Impact Award Closed Loop Technologies Clinical, Physiological and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (DP3) Apply for RFA DK 14 014 Funding Number: RFA DK 14 014 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Diabetes Impact Award Closed Loop Technologies Development and Integration of Novel Components for an Automated Artificial Pancreas System (DP3) Apply for RFA DK 14 015 Funding Number: RFA DK 14 015 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Nutrition Obesity Research Centers (NORCs) (P30) Apply for RFA DK 14 002 Funding Number: RFA DK 14 002 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Silvio O. Conte Digestive Diseases Research Core Centers (P30) Apply for RFA DK 14 012 Funding Number: RFA DK 14 012 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Increasing the Quality and Efficiency of Clinical Trials (R18) Apply for RFA FD 14 017 Funding Number: RFA FD 14 017 Agency: Food Drug Administration Category: Food and Nutrition Health Funding Amount: $7,500,000 |
| U.S. India Bilateral Collaborative Research Partnerships (CRP) on Diabetes Research (R21) Apply for RFA DK 14 006 Funding Number: RFA DK 14 006 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $275,000 |
| Polycystic Kidney Disease (PKD) Research and Translation Core Centers (P30) Apply for RFA DK 14 013 Funding Number: RFA DK 14 013 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Research Using Biosamples From Selected Type 1 Diabetes Clinical Studies (DP3) Apply for PAR 14 257 Funding Number: PAR 14 257 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $4,000,000 |
| Research Using Subjects From Selected Type 1 Diabetes Clinical Studies (Living Biobank) (DP3) Apply for PAR 14 258 Funding Number: PAR 14 258 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $7,000,000 |
| Chronic Kidney Disease Biomarkers Consortium (CKD BioCon) (U01) Apply for RFA DK 14 011 Funding Number: RFA DK 14 011 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $450,000 |
| Improving Diabetes Management in Young Children with Type 1 Diabetes (DP3) Apply for RFA DK 14 022 Funding Number: RFA DK 14 022 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Critical Path Public Private Partnerships Apply for RFA FD 14 089 Funding Number: RFA FD 14 089 Agency: Food Drug Administration Category: Food and Nutrition Health Funding Amount: $10,500,000 |
| NIDDK Mentored Research Scientist Development Award (K01) Apply for PAR 14 266 Funding Number: PAR 14 266 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition Data Coordinating Center for The Environmental Determinants of Diabetes in the Young (TEDDY) Study (UC4) Apply for RFA DK 14 505 Funding Number: RFA DK 14 505 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $20,000,000 |
| NIAID SBIR Technology Transfer Direct Phase II (SBIR TT) (R44) Apply for RFA AI 14 049 Funding Number: RFA AI 14 049 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 14 501", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.